Urinary alanine-aminopeptidase (AAP) excretion in patients with urinary tract infection treated with ceftazidime (CAZ) or cefotaxime (CTX) plus tobramycin (TOB).
It is well known that some antibiotics are particularly nephrotoxic. In the present study we investigated kidney function and AAP excretion (as an index of nephrotoxicity) in patients with urinary tract infection treated with CAZ or CTX plus TOB. The main cause of infection was E. coli in both treated groups. After 10 days of treatment similar beneficial effects were stated in both groups. At the end of treatment urinary AAP excretion in both groups was higher than before treatment. Despite a significant increase in urinary AAP in only one patient of each group, the serum creatinine level rose by more than 45 mumol/l. Monitoring of urinary AAP may be useful in early detection of nephrotoxicity caused by antibiotics.
Wiecek
A
A
Department of Nephrology, Silesian School of Medicine, Katowice, Poland.
Kokot
F
F
Grzeszczak
W
W
D000328:Adult; D000626:Aminopeptidases / Q000652:urine*; D018826:CD13 Antigens; D002439:Cefotaxime / Q000627:therapeutic use*; D002442:Ceftazidime / Q000627:therapeutic use*; D004796:Clinical Enzyme Tests; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000201:enzymology; D005260:Female; D006801:Humans; D007677:Kidney Function Tests; D008297:Male; D014031:Tobramycin / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000201:enzymology*
D002442:Ceftazidime; D003404:Creatinine; D000626:Aminopeptidases; D018826:CD13 Antigens; D002439:Cefotaxime; D014031:Tobramycin